- Home
- ELLO vs ELDN Comparison
ELLO vs ELDN Comparison
Compare ELLO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- ELDN
- Stock Information
- Founded
- ELLO 1987
- ELDN 2004
- Country
- ELLO Israel
- ELDN United States
- Employees
- ELLO N/A
- ELDN N/A
- Industry
- ELLO Electric Utilities: Central
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- ELDN Health Care
- Exchange
- ELLO Nasdaq
- ELDN Nasdaq
- Market Cap
- ELLO 208.2M
- ELDN 178.4M
- IPO Year
- ELLO 1995
- ELDN N/A
- Fundamental
- Price
- ELLO N/A
- ELDN $3.08
- Analyst Decision
- ELLO
- ELDN Strong Buy
- Analyst Count
- ELLO 0
- ELDN 2
- Target Price
- ELLO N/A
- ELDN $12.50
- AVG Volume (30 Days)
- ELLO 4.7K
- ELDN 640.9K
- Earning Date
- ELLO 06-30-2025
- ELDN 08-18-2025
- Dividend Yield
- ELLO N/A
- ELDN N/A
- EPS Growth
- ELLO N/A
- ELDN N/A
- EPS
- ELLO 0.43
- ELDN N/A
- Revenue
- ELLO $44,405,534.00
- ELDN N/A
- Revenue This Year
- ELLO N/A
- ELDN N/A
- Revenue Next Year
- ELLO N/A
- ELDN N/A
- P/E Ratio
- ELLO $45.19
- ELDN N/A
- Revenue Growth
- ELLO N/A
- ELDN N/A
- 52 Week Low
- ELLO $11.30
- ELDN $2.30
- 52 Week High
- ELLO $20.81
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- ELLO 61.85
- ELDN 59.25
- Support Level
- ELLO $16.61
- ELDN $2.60
- Resistance Level
- ELLO $18.54
- ELDN $2.91
- Average True Range (ATR)
- ELLO 0.89
- ELDN 0.19
- MACD
- ELLO 0.31
- ELDN 0.04
- Stochastic Oscillator
- ELLO 77.96
- ELDN 85.71
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.